Clearmind submits recommendations to FDA on future therapeutic use of psychedelic drugs

• Clearmind submitted recommendations to the FDA on potential future therapeutic use of psychedelic drugs under Docket FDA-2026-N-7542.
• Filing urged regulatory pathways that could support at-home use of non-hallucinogenic neuroplastogens for alcohol use disorder.
• Company also pressed for expanded federal research partnerships, citing ongoing trials at Yale University, Johns Hopkins University.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070840PRIMZONEFULLFEED9841367) on October 07, 2026, and is solely responsible for the information contained therein.